A prospective open-label phase 2 study will be designed to assess the efficacy of oral
arsenic trioxide plus azacitidine in preventing relapses in patients with NPM1-mutant AML.
After screening and eligibility assessment, patients will receive treatment with oral arsenic
trioxide plus azacitidine for 12 months. The recruitment period will last for 24 months and
it will take approximately 36 months for study completion.